The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

“…<p>(<b>A</b>) Genome-wide expression of 5′ splice sites, 3′ splice sites, and introns are increased relative to exons upon treatment of HeLa cells with isoginkgetin (30 µM, 18 hours), based on total RNA-Seq (dUTP method <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone.0089673-Parkhomchuk1" target="_blank">[18]</a>, Illumina). …”

Mesothelin expression and RG7787 uptake is decreased in KLM-1-R. by Kevin Hollevoet (710450)

“…<p><b>A</b>: Surface mesothelin levels are 5-fold lower in resistant KLM-1 (KLM-1-R) compared to KLM-1. …”

a-f. PSP significantly decreased NP-specific IgM responses at days 4 and 21 compared to ACACIA. by Bhagwant Kaur Sekhon (847697)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Subnetwork of core DE genes with ≥5.0 degree and a fold change of ≥2.0 (50 nodes and 97 edges). by Reena Arora (1464781)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

How the variation in inhibitor concentration throughout one day affects the value of IC₅₀/(IC₅₀ + [R]) for different Abl1 inhibitors. by J. Roadnight Sheehan (20141887)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

Subjects:

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

Subjects:

LOH resulting in 189R/R produces a strong decrease in drug susceptibility. by Pétra Vande Zande (17628246)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)

Definitions of the features selected [50]. by Yu Zhang (12946)